NCT03592199View on ClinicalTrials.gov

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

PHASE2UnknownINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2022

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy

Trial Locations (1)

01246000

Instituto do Cancer do Estado de São Paulo, São Paulo

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Instituto do Cancer do Estado de São Paulo

OTHER

NCT03592199 - Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | Biotech Hunter | Biotech Hunter